Revenue from operations increased sequentially by 13% to Rs. 891 crores, down 2% year-on-year First half FY25 revenue was broadly flat, in line with our guidance, at Rs. 1,681 crores Syngene International Limited today announced its second quarter and half year financial results. Revenue from
Full-year revenue from operations up 9% to Rs 3,489 Cr, PAT1 up 12% to Rs 519 Cr Fourth quarter revenue from operations declined 8% year-on-year to Rs. 917 Cr, PAT1 increased 6% to Rs. 189 Cr Syngene International Limited today announced its full-year
Company reports resilient performance in the nine months to date: revenue from operations up 17% to Rs 2,572 crores, PAT up 16% to Rs 330 crores (before exceptional items) Syngene International Limited today announced its third quarter financial results. Reported revenue from operations for the quarter
Revenue from operations up 18.5% to Rs 910 crores, PAT (before exceptional items) up 20% to Rs 122 crores First half FY24 revenue from operations was up 22% to Rs 1,718 crores; Profit after tax (before exceptional items) up 23% to Rs 215 crores Syngene International Limited
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24 US FDA approval for API manufacturing plant in Mangalore received Acquisition of land in Hyderabad to support long term growth in research services Syngene International Limited
Syngene (or the “Company”) today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The companies have entered into a binding term sheet and, on completion of the transaction, the site will add 20,000 liters of installed
